Taficita-EM (Descovy)

Taficita-EM is a next-generation, bioequivalent generic PrEP medication that combines Tenofovir Alafenamide (25 mg) and Emtricitabine (200 mg) in a highly effective fixed-dose tablet. Manufactured by Mylan Laboratories (a Viatris company), one of the world's most reputable pharmaceutical leaders, this advanced HIV prevention treatment serves as the generic version of Descovy®, offering a superior safety profile for bone density and kidney function compared to older TDF-based regimens. Specifically designed for HIV-negative individuals at risk, Taficita-EM provides a potent, smaller-sized, and clinically proven HIV prophylaxis solution that maintains high efficacy with a reduced metabolic impact, ensuring long-term health and maximum protection.